A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Volrustomig (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms eVOLVE-Cervical; eVOLVECervical
Sponsors AstraZeneca

Most Recent Events

22 Nov 2024 Planned number of patients changed from 1000 to 800.
22 Nov 2024 Planned End Date changed from 24 Oct 2029 to 18 Oct 2029.
22 Nov 2024 Planned primary completion date changed from 19 Feb 2027 to 17 Nov 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight